Medtronic Accelerates Hugo RAS Platform to Challenge Intuitive Surgical's Da Vinci Dominance

Home of Medical Devices

Pioneer in Medical Device Media Coverage

Sharing Professional Medical Device Knowledge

Follow

Source:Device Home,Reproduction without authorization is prohibited, and may only be reproduced after 24 hours.

MedTech Home has learned that the medical technology giantMedtronicRecentAccelerating its surgical proceduresRobotThe product's pace. This Dublin-headquartered company last year12Obtained in MonthFDAApproval, shallHugoRobot-assisted surgery (RAS) Used in urological surgery.

Medtronic is currently developing a series of plans and milestones for the platform, which will be integrated withIntuitive Surgical (Intuitive Surgical）in direct competition with the da Vinci system.

CurrentlyHugoKey Milestones and Indications for Robotics:

InEquipment and Consumables CostsIn this aspect, Medtronic also has certain advantages.HugoThe equipment price is approximately that of the da Vinci system.60-70%, the cost of disposable materials for a single procedure is significantly lower than that of the high-end disposables used with the da Vinci system.Medtronic claimsHugoCan reduce the direct hospital costs of radical prostatectomy11%。

DespiteHugoCompetitive in terms of technological differentiation, cost advantages, and ecosystem integration, but facing da Vinci's overwhelming20years of market monopoly, exceeding11,000the global installed base and robust surgeon training system,HugoIt will be difficult to shake its leadership position in the short term. MedtronicHugofaced withThe following multipleChallenge：

Therefore, Medtronic’s management clearly recognizes the discrepancies and issues, and they have established clear current goals and strategies. Furthermore, theyHugoSurgical RobotMaintain an optimistic attitude toward development.

Senior Vice President and President, Medtronic Surgical BusinessMatt Andersonstated: “These milestones and innovative technologies will unlock our ability to enhance the value of our partnerships in the field of general and gynecological surgery.” “This is not merely an expansion of the portfolio;“This is part of our ongoing commitment to integrating devices, intelligence, and human expertise into a unique surgical ecosystem—a platform that ensures every patient, regardless of location, receives optimal surgical care.”

At an earnings conference call, Jeff, Chairman and Chief Executive Officer of Medtronic· Martha discussedHugoSuccess in the Past Quarter.HeIndicates:

"We are now also beginning to see"Hugo"The substantial impact brought by surgical robot systems," "Our global growth in surgical volume is the market's"2to3times, and utilization rates are also increasing. Last quarter, we launched in the United StatesHugoUrology Program: Systems were installed at leading institutions, and the first patients were treated. Feedback from the surgical teams has been positive, both in terms of experience and early clinical outcomes.

MedtronicHugoIt is the da Vinci system25In the history of annual monopoliesThe first truly credible large-scale competitor, but"Frontal Competition"This is more reflected in providing choices to the market and exerting price pressure, rather than replacing da Vinci in the short term. This is a marathon, not a sprint; the outcome will gradually become apparent over a decade-long horizon.